Daily Respiratory Research Analysis
Analyzed 155 papers and selected 3 impactful papers.
Summary
Three impactful respiratory studies emerged: a prespecified secondary analysis of the DANFLU-2 randomized trial showed high-dose influenza vaccine reduces cardiorespiratory and influenza hospitalizations in older adults regardless of diabetes status; an open-label RCT found budesonide–formoterol reliever therapy lowers FeNO versus terbutaline in adults on maintenance inhaled corticosteroids; and a multinational CHEST analysis identified patient-level risk factors for Pseudomonas aeruginosa in ICU-related nosocomial respiratory infections to guide empiric therapy.
Research Themes
- Optimizing respiratory infection prevention via vaccination strategies in high-risk older adults
- Anti-inflammatory reliever therapy in asthma on maintenance ICS
- Risk stratification and stewardship for ICU nosocomial respiratory infections
Selected Articles
1. High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Diabetes: A Secondary Analysis of the DANFLU-2 Randomized Clinical Trial.
In DANFLU-2 (n=332,438; 13.2% with diabetes), high-dose influenza vaccine reduced cardiorespiratory, cardiovascular, and influenza hospitalizations compared with standard-dose in adults ≥65 years. Effects were similar in those with and without diabetes. A diabetes duration >5 years modified benefit for cardiorespiratory hospitalization (rVE ~20% vs ~0% if ≤5 years).
Impact: This large randomized analysis directly informs vaccine dosing policy for older adults, including those with diabetes, a high-risk group for severe respiratory outcomes.
Clinical Implications: For adults ≥65 years, high-dose influenza vaccination should be preferred to reduce cardiorespiratory hospitalizations, regardless of diabetes status; longer diabetes duration (>5 years) may further support prioritization of high-dose vaccine.
Key Findings
- Among 332,438 randomized participants (48.6% female), 13.2% had diabetes.
- High-dose vaccine reduced cardiorespiratory hospitalization versus standard-dose (rVE 7.4% in diabetes; 5.3% without diabetes; interaction P=0.69).
- Cardiovascular hospitalization was reduced (rVE 12.0% in diabetes; 6.0% without; interaction P=0.38).
- Influenza hospitalization reduction was robust (rVE 41.6% in diabetes; 44.3% without; interaction P=0.87).
- Diabetes duration >5 years modified rVE for cardiorespiratory hospitalization (20.4% vs −0.4% if ≤5 years; interaction P=0.03).
Methodological Strengths
- Prespecified secondary analysis within a large pragmatic individually randomized trial across multiple seasons
- Outcomes ascertained via nationwide health registries with minimal loss to follow-up
Limitations
- Open-label design may influence health-seeking behavior though registry outcomes mitigate bias
- Secondary analysis not powered for all subgroup interactions; effect sizes modest for composite outcomes
Future Directions: Evaluate cost-effectiveness and equity impacts of high-dose vaccination; assess durability across seasons and interactions with comorbidities beyond diabetes.
IMPORTANCE: Influenza infection poses a substantial risk of severe complications, particularly in older adults and high-risk populations, such as individuals with diabetes. The high-dose inactivated influenza vaccine (HD-IIV) has demonstrated superior efficacy against influenza infection compared with the standard-dose inactivated influenza vaccine (SD-IIV) among adults 65 years or older. However, there is limited evidence on its effectiveness in preventing severe respiratory and cardiovascular outcomes in individuals with diabetes. OBJECTIVE: To investigate the relative vaccine effectiveness (rVE) of HD-IIV vs SD-IIV against severe respiratory and cardiovascular outcomes according to diabetes status and across diabetes subgroups. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of DANFLU-2, a pragmatic, open-label, individually randomized clinical trial conducted in Denmark during the 2022/2023 to 2024/2025 influenza seasons. Adults 65 years or older were eligible for inclusion regardless of comorbidities. Data were obtained from nationwide health registries and analyzed from June to October 2025.
2. Budesonide-formoterol versus terbutaline reliever in adults with asthma using maintenance inhaled corticosteroids in New Zealand (INFORM ASTHMA): an open-label, parallel-group, randomised, controlled, phase 4 trial.
Among 181 randomized adults on maintenance budesonide 200 μg, budesonide–formoterol reliever reduced FeNO by a geometric mean 18.5% versus terbutaline at 26 weeks. Adverse event rates were similar between groups and no deaths occurred. Findings support anti-inflammatory reliever use in adults using maintenance ICS.
Impact: Direct randomized evidence fills a key gap by testing an anti-inflammatory reliever strategy in patients already on maintenance ICS, using a type 2 inflammation biomarker (FeNO).
Clinical Implications: In adults on maintenance ICS, budesonide–formoterol as reliever can be considered to reduce airway type 2 inflammation; trials powered for exacerbations remain needed to inform outcomes beyond biomarkers.
Key Findings
- Randomized 181 adults (mean FeNO baseline ~62–68 ppb) to budesonide–formoterol vs terbutaline reliever with maintenance budesonide.
- At 26 weeks, FeNO decreased more with budesonide–formoterol: 18.50% reduction versus terbutaline (p=0.024).
- Adverse events occurred in 83% vs 78% (RR 1.06; p=0.46), with no deaths.
- Supports anti-inflammatory reliever in mild–moderate asthma already receiving maintenance ICS.
Methodological Strengths
- Randomized, stratified, parallel-group design with predefined biomarker primary endpoint
- Phase 4 pragmatic setting including hospital and primary care sites
Limitations
- Open-label design and modest sample size
- Primary endpoint is a biomarker; not powered to detect exacerbation differences
Future Directions: Larger, blinded trials assessing exacerbations, symptom control, and healthcare utilization; evaluate phenotype-specific responses and adherence effects.
BACKGROUND: Recommendations for the use of inhaled corticosteroid-formoterol reliever-based regimens are limited by the absence of randomised controlled trials (RCTs) in patients with asthma using maintenance inhaled corticosteroids, and scarce evidence for the effect on type 2 airway inflammation. We aimed to examine the clinical efficacy and safety of maintenance inhaled corticosteroids plus budesonide-formoterol reliever or terbutaline reliever in patients with mild-to-moderate asthma. METHODS: This open-label, parallel-group, randomised, controlled, phase 4 trial was conducted at Wellington Hospital and two community-based primary care facilities in New Zealand. Eligible participants were aged 16-75 years, had a self-reported doctor's diagnosis of asthma, were using reliever only therapy or maintenance inhaled corticosteroids with short-acting β2-agonist reliever therapy, and were registered with a general practitioner.
3. Pseudomonas aeruginosa in patients with Nosocomial Respiratory Infections: A secondary analysis of the European Network for ICU-Related Respiratory Infections (ENIRRIs).
In 1,059 ICU patients with NRI across 12 countries, Pseudomonas aeruginosa was identified in 14.5% (MDR 19.6%; carbapenemase 11.1%). Ventilator-associated pneumonia accounted for 66% of P. aeruginosa cases. COPD GOLD D, autoimmune disease, chronic kidney disease, and day-1 acute kidney injury were key risk factors. High empirical anti-Pseudomonas therapy use was noted without mortality differences.
Impact: Provides multinational, contemporary risk stratification for P. aeruginosa in ICU nosocomial respiratory infections, informing empiric antibiotic stewardship and diagnostics.
Clinical Implications: Consider heightened Pseudomonas coverage in ICU NRI when COPD GOLD D, autoimmune disease, CKD, or early AKI are present; align empiric therapy with local ecology and de-escalate based on cultures.
Key Findings
- P. aeruginosa prevalence was 14.5% (n=153) among microbiology-tested ICU NRI patients.
- Resistance mechanisms present in 5.1%; 19.6% were MDR and 11.1% carbapenemase producers.
- Ventilator-associated pneumonia comprised 66% of P. aeruginosa cases.
- Risk factors: COPD GOLD D, autoimmune disease, chronic kidney disease, and day-1 acute kidney injury.
- No significant mortality difference between patients with and without P. aeruginosa; empirical anti-Pseudomonas use was common.
Methodological Strengths
- Prospective multinational cohort with standardized case capture across 12 countries
- Use of multivariable models and machine learning (LASSO/Elastic Net/Random Forest) to identify risk factors
Limitations
- Secondary analysis; heterogeneity in local microbiology and practices may introduce residual confounding
- Mortality analyses may be underpowered for specific pathogen–outcome interactions
Future Directions: Develop and validate bedside risk scores to target empiric anti-Pseudomonas coverage; evaluate stewardship interventions and rapid diagnostics to reduce unnecessary broad-spectrum use.
BACKGROUND: Nosocomial respiratory infections (NRIs) are the most common complication among ICU patients, with Pseudomonas aeruginosa frequently identified. However, its global prevalence and associated risk factors remain unclear. RESEARCH QUESTION: Among ICU patients with NRI, what is the international prevalence of P. aeruginosa, and which clinical factors are associated with an increased risk? STUDY DESIGN AND METHODS: This secondary analysis used data from the European Network for ICU-Related Respiratory Infections (ENIRRI), a prospective cohort study conducted across 12 countries from May 2016 to August 2019. Data from 1,059 NRI patients who underwent microbiological testing were analyzed. Descriptive statistics, imputation of missing data, LASSO regression, Elastic Net, Random Forest, and multivariable logistic regression were applied. Model performance was assessed using McFadden's R